PolyPid to Participate in Upcoming Investor Conferences

Rhea-AI Summary

PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharma company focused on enhancing surgical outcomes, announced its participation in several upcoming investor conferences. The events include:

• Aegis Capital Corp. Virtual Conference: May 3, 2023, at 10:30 AM ET
• Sidoti & Company Micro-Cap Virtual Conference: May 11, 2023, at 9:15 AM ET
• JMP Securities Life Sciences Conference: May 15, 2023, at 2:30 PM ET

During these conferences, PolyPid's management will engage in one-on-one investor meetings. The company aims to provide insights into its lead product candidate, D-PLEX100, currently in Phase 3 trials for preventing surgical site infections. Furthermore, PolyPid is exploring OncoPLEX for solid tumor treatments, including glioblastoma.

PETACH TIKVA, Israel, April 24, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that members of management will participate in the following upcoming investor conferences:

Aegis Capital Corp. Virtual Conference
Presentation Date: Wednesday, May 3, 2023
Presentation Time: 10:30 AM Eastern Time

Sidoti & Company Micro-Cap Virtual Conference
Presentation Date: Thursday, May 11, 2023
Presentation Time: 9:15 AM Eastern Time

JMP Securities Life Sciences Conference in New York City
Fire Side Chat Date: Monday, May 15, 2023
Fire Side Chat Time: 2:30 PM Eastern Time

The PolyPid management team will participate in one-on-one investor meetings during these events. Investors interested in meeting with the Company around the conferences should contact their Aegis Capital, Sidoti, or JMP Securities representative.

About PolyPid

PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX₁₀₀ is in Phase 3 clinical trials for the prevention of abdominal colorectal surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for treatment of solid tumors, beginning with glioblastoma.

For additional Company information, please visit http://www.polypid.com and follow us on Twitter and LinkedIn.

Contacts:
PolyPid Ltd. 
Ori Warshavsky
COO – US
908-858-5995
IR@Polypid.com

Investors:
Brian Ritchie
LifeSci Advisors
212-915-2578
britchie@lifesciadvisors.com

FAQ

What investor conferences is PolyPid Ltd. participating in May 2023?

PolyPid Ltd. will participate in the Aegis Capital Corp. Virtual Conference on May 3, Sidoti & Company Micro-Cap Virtual Conference on May 11, and JMP Securities Life Sciences Conference on May 15, 2023.

What is the presentation time for the Aegis Capital Corp. Virtual Conference?

The presentation at the Aegis Capital Corp. Virtual Conference is scheduled for May 3, 2023, at 10:30 AM Eastern Time.

What is D-PLEX100, the product candidate of PolyPid?

D-PLEX100 is PolyPid's lead product candidate currently in Phase 3 clinical trials aimed at preventing abdominal colorectal surgical site infections.

When is the JMP Securities Life Sciences Conference taking place?

The JMP Securities Life Sciences Conference will take place on May 15, 2023, at 2:30 PM Eastern Time.

What new developments is PolyPid exploring apart from D-PLEX100?

PolyPid is in preclinical stages testing OncoPLEX for the treatment of solid tumors, starting with glioblastoma.